World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
77
Citations
18025
World Ranking
1368
National Ranking
117

Overview

Stephen H. Gillespie is affiliated with the University of St Andrews in the United Kingdom and has contributed extensively to the field of medicine, with a focus on epidemiology and infectious diseases. Their research spans several interconnected areas including tuberculosis, bacterial identification, antibiotic resistance, and respiratory infections.

The scientist's main fields of study include:

  • Medicine

Within this broad field, Gillespie's subfields of study are:

  • Epidemiology
  • Infectious Diseases
  • Clinical Biochemistry
  • Surgery
  • Applied Microbiology and Biotechnology

Their work primarily addresses topics such as:

  • Tuberculosis Research and Epidemiology
  • Mycobacterium research and diagnosis
  • Bacterial Identification and Susceptibility Testing
  • Antibiotic Use and Resistance
  • Pneumonia and Respiratory Infections
  • Urinary Tract Infections Management
  • Global Maternal and Child Health

Stephen H. Gillespie has published in a variety of venues, frequently contributing to:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • SSRN Electronic Journal
  • The International Journal of Tuberculosis and Lung Disease
  • The Lancet Microbe
  • Frontiers in Antibiotics

Recent notable papers include:

  • "Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay," 2020, Thorax
  • "Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies," 2022, Clinical Microbiology Reviews
  • "The role of multidimensional poverty in antibiotic misuse: a mixed-methods study of self-medication and non-adherence in Kenya, Tanzania, and Uganda," 2022, The Lancet Global Health
  • "Update on the diagnosis of tuberculosis," 2023, Clinical Microbiology and Infection
  • "Perspective for Precision Medicine for Tuberculosis," 2020, Frontiers in Immunology

Frequent co-authors collaborating with Gillespie comprise:

  • Wilber Sabiiti
  • Derek J. Sloan
  • Matthew T. G. Holden
  • Gibson Kibiki
  • Stephen E. Mshana

Best Publications

  • Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

    Stephen H. Gillespie;Angela M. Crook;Timothy D. McHugh;Carl M. Mendel

  • Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective

    Stephen H. Gillespie

  • Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology

    Claudio U. Köser;Matthew J. Ellington;Edward J. P. Cartwright;Edward J. P. Cartwright;Stephen H. Gillespie

  • Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial

    C Chintu;GJ Bhat;AS Walker;V Mulenga

  • The bacteriology of pleural infection by genetic and standard methods and its mortality significance.

    Nick A. Maskell;Sarah Batt;Emma L. Hedley;Christopher W. H. Davies

  • New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

    Alimuddin I Zumla;Alimuddin I Zumla;Stephen H Gillespie;Michael Hoelscher;Patrick P J Philips

  • High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

    Martin J Boeree;Norbert Heinrich;Rob Aarnoutse;Andreas H Diacon

  • A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis

    M.J. Boeree;A.H. Diacon;R. Dawson;K. Narunsky

  • Physiological Cost of Rifampin Resistance Induced In Vitro in Mycobacterium tuberculosis

    O. J. Billington;T. D. McHugh;S. H. Gillespie

  • Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment

    Jakko van Ingen;Rob E. Aarnoutse;Peter R. Donald;Andreas H. Diacon

  • The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

    Roly D. Gosling;Leonard O. Uiso;Noel E. Sam;Emily Bongard

  • Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study

    Josephine M Bryant;Simon R Harris;Julian Parkhill;Rodney Dawson

  • Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment

    Sven O. Friedrich;Andrea Rachow;Andrea Rachow;Elmar Saathoff;Kasha Singh

  • Gram-positive cocci

    Unknown

  • Blood culture bottle culture of pleural fluid in pleural infection

    S. M. Menzies;N. M. Rahman;J. M. Wrightson;H. E. Davies

  • Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution.

    T. Yeghen;C. C. Kibbler;H. G. Prentice;L. A. Berger

  • Anti-tuberculosis medication and the liver: dangers and recommendations in management

    N P Thompson;M E Caplin;M I Hamilton;S H Gillespie

  • Principles and Practice of Clinical Bacteriology

    Stephen Gillespie;Peter M Hawkey

  • Activity of moxifloxacin against mycobacteria.

    S. H. Gillespie;O. Billington

  • Molecular epidemiology of tuberculosis in London 1995–7 showing low rate of active transmission

    H Maguire;J W Dale;T D McHugh;P D Butcher

  • Principles and practice of clinical parasitology

    Stephen H. Gillespie;Richard D. Pearson

  • Pathogenesis of pneumococcal infection.

    S.H. Gillespie;I. Balakrishnan

  • Mandell, Douglas, and Bennett's principles and practice of infectious diseases

    Stephen H Gillespie

Frequent Co-Authors

Timothy D. McHugh
Timothy D. McHugh University College London
Andrew Nunn
Andrew Nunn University College London
Michael Hoelscher
Michael Hoelscher Ludwig-Maximilians-Universität München
Marc Lipman
Marc Lipman Royal Free London NHS Foundation Trust
Anne Osbourn
Anne Osbourn John Innes Centre
Geoffrey L. Smith
Geoffrey L. Smith University of Oxford
Michael E. P. Murphy
Michael E. P. Murphy University of British Columbia
Matthew T. G. Holden
Matthew T. G. Holden University of St Andrews
Kishan Dholakia
Kishan Dholakia University of St Andrews
Roly Gosling
Roly Gosling University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Microbiology opens doors to various related fields and career options, many of which offer flexible online learning opportunities. For those interested in expanding their knowledge in health sciences, exploring online medical programs can be a convenient way to gain essential expertise without relocating.

Public health is another popular pathway closely tied to microbiology. Many students look for the best easiest mph online programs to get into, allowing for a smoother transition into public health careers that often collaborate with microbiologists on health initiatives and disease prevention.

For individuals passionate about working with children, considering a career as a child life specialist may be appealing. The role’s salary and growth potential are detailed in resources about child life specialists salary, making it easier to evaluate this fulfilling career path.

Importantly, those with diverse backgrounds, including individuals with prior convictions, can also advance their education. The best degrees for felons include options that pave the way to careers in health and science, expanding opportunities for all learners.

Best Scientists Citing Stephen H. Gillespie

Trending Scientists

Recently Published Articles